Michael P Dube insider trades: Intellia Therapeutics (NTLA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | NTLA | ↓ Sell | 1,864 | $12.43 | $23K | Direct | Oct 6, 2026 (4d) |
| Jul 1, 2026 | NTLA | ↓ Sell | 2,641 | $16.78 | $44K | Direct | Jul 6, 2026 (5d) |
| Jan 5, 2026 | NTLA | ↓ Sell | 2,989 | $9.21 | $28K | Direct | Jan 7, 2026 (2d) |
| Oct 1, 2025 | NTLA | ↓ Sell | 1,871 | $17.38 | $33K | Direct | Oct 3, 2025 (2d) |
| Jul 2, 2025 | NTLA | ↓ Sell | 2,503 | $9.95 | $25K | Direct | Jul 3, 2025 (1d) |
| Jan 3, 2025 | NTLA | ↓ Sell | 1,372 | $12.18 | $17K | Direct | Jan 7, 2025 (4d) |
| Oct 2, 2024 | NTLA | ↓ Sell | 2,012 | $19.01 | $38K | Direct | Oct 4, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NTLA insiders
Open-market trades in the last 12 months
About Michael P Dube's insider trades
Michael P Dube is VP, Chief Accounting Officer at Intellia Therapeutics (NTLA). Since Oct 2, 2024, Michael has reported no open-market purchases and 7 sales worth $207K on SEC Form 4. In the last 12 months: 3 sales ($95K).
Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NTLA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.